Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of UBT251 injection in overweight or obese adults
ChiCTR2500113817Phase 2Completed
- Sponsor
- The Second Xiangya Hospital
- Start
- Dec 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of UBT251 in obesity and Overweight (5 arms), sponsored by The Second Xiangya Hospital. Primary endpoint: Body weight at Week 24. Started Dec 2025; status: completed.
02
Drugs
UBT251
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on ChiCTR2500113817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113817.